Janux Therapeutics JANX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.83M-29.7% | $52.33M-87.8% | $48.39M+80.9% | $52.45M+258% | $73.74M-65.3% | ||
| $904.56M-3.8% | $914.23M+53.8% | $940.6M+49.0% | $943.57M+49.4% | $940.4M+114% | ||
| —— | —— | —— | —— | —— | ||
| $1B-2.1% | $975.89M-5.6% | $998.09M+49.8% | $1.01B+51.9% | $1.02B+55.4% | ||
| $3.55M-28.3% | $3.85M-20.8% | $4.31M-19.7% | $4.69M-21.1% | $4.95M-24.1% | ||
| $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% | $1.05B+52.5% | ||
| $15.22M+50.8% | $14.19M+42.0% | $13.25M+57.9% | $12.32M+46.0% | $10.09M+11.0% | ||
| —— | —— | —— | —— | —— | ||
| $58.92M+237% | $25M+43.2% | $27.83M+62.1% | $21.38M+85.2% | $17.5M+65.0% | ||
| $86.69M+126% | $44.74M+15.5% | $48.21M+23.9% | $41.7M+23.6% | $38.3M+15.3% | ||
| $60K+1.7% | $60K+1.7% | $60K+15.4% | $59K+13.5% | $59K+15.7% | ||
| -$375.74M-43.8% | -$351.38M-47.8% | -$319.44M-46.8% | -$295.12M-55.8% | -$261.27M-42.4% | ||
| $941.54M-7.0% | $956.82M-6.4% | $976.56M+48.8% | $990.52M+50.6% | $1.01B+54.4% | ||
| $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% | $1.05B+52.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Janux Therapeutics's total assets?
- Janux Therapeutics (JANX) holds $1.0B in total assets, down 2.1% year over year.
- How much debt does Janux Therapeutics have?
- Janux Therapeutics carries $21.6M in total debt against $941.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Janux Therapeutics have?
- Janux Therapeutics holds $51.8M in cash and equivalents.
- Can Janux Therapeutics cover its short-term obligations?
- Its current ratio is 17.01 — current assets exceed current liabilities.
- Where does Janux Therapeutics's balance sheet data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
